Docetaxel in the management of patients with head and neck squamous cell carcinoma.

@article{Bernier2008DocetaxelIT,
  title={Docetaxel in the management of patients with head and neck squamous cell carcinoma.},
  author={Jacques Bernier and Conny Vrieling},
  journal={Expert review of anticancer therapy},
  year={2008},
  volume={8 7},
  pages={1023-32}
}
The taxanes play a significant role in the treatment of various solid tumors of epithelial origin. Docetaxel is the most extensively studied taxane in prospective head and neck cancer trials and has been investigated as induction chemotherapy or in combination with radiotherapy in locally advanced squamous cell carcinomas of the head and neck (HNSCC) and as palliation in recurrent or metastatic disease. The data in locally advanced disease are particularly compelling. Three recently reported… CONTINUE READING